Here's the current status as of March 2026:
Legal status: Complicated. FDA removed tirzepatide from the shortage list in October 2024 and has been issuing warning letters and cease-and-desist orders to compounders. HOWEVER, multiple lawsuits are challenging these enforcement actions, and some pharmacies have obtained temporary restraining orders allowing them to continue compounding.
Availability: Reduced but not eliminated. Several 503B facilities stopped voluntarily. Others are still compounding under legal protection from court orders. Some 503A pharmacies argue they're exempt from the enforcement because they compound on a patient-specific basis.
Pricing (where available):
- Compounded tirzepatide 10mg vial: $150-275/month
- Compounded tirzepatide 30mg vial: $300-450 (multi-month supply at lower doses)
Compare to brand Mounjaro/Zepbound at $1,050-1,200/month without insurance.